Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;18(30):3435-3447.
doi: 10.2217/fon-2022-0578. Epub 2022 Sep 14.

Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer

Holly Guy  1 , Carol Hawkes  2 , Lydia Walder  1 , Izabela A Malinowska  3 , Divya Gupta  3
Affiliations
Free article

Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer

Holly Guy et al. Future Oncol. 2022 Sep.
Free article

Abstract

Aim: To review safety and efficacy outcomes in studies of first-line maintenance therapies for advanced ovarian cancer. Methods: A systematic literature review was performed (27 February 2020) to identify clinical outcomes including progression-free survival (PFS), overall survival (OS) and Grade ≥3 adverse events. Results: Overall 50 references met prespecified criteria; 18 studies evaluated 10 different agents, including PARP inhibitors. PFS was an end point in 16 trials and OS in 12 trials. PARP inhibitors reported better PFS hazard ratios (HRs: 0.59-0.68) compared with other classes; no mature OS data were identified. Safety reporting was inconsistent. Conclusion: Reported PFS HRs were better for PARP inhibitors than for other ovarian cancer maintenance therapies; overall survival data remain immature.

Keywords: BRCA mutation; PARP inhibitor; first-line maintenance; ovarian cancer; progression-free survival; systematic literature review.

Plain language summary

This article reports the results from a systematic literature review (SLR), enabling a critical and unbiased comparison of clinical studies, of responses and side effects of first-line maintenance therapies used for advanced ovarian cancer. Overall, this SLR supports the use of PARP inhibitors as maintenance therapy for patients with advanced ovarian cancer as they demonstrated a greater effect on delaying further disease progression than other drug types assessed. However, due to large differences between the clinical studies included (e.g. design of the trial), direct comparisons between first-line maintenance therapies must be made with caution. Healthcare professionals must factor individual patient circumstances when choosing the most appropriate therapy.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources